Baiji Shenzhou / Anjin cooperation "injection with perintomo double resistance" was approved for listing

On December 7, NMPA issued an approval for the domestic market of Amgen's "Injection Perintomo Double Resistance" for the treatment of adult patients with R/R pre-B-cell acute lymphoblastic leukemia (ALL).
based on previous cooperation between Amjin and Baiji, the commercialization of the variety after its listing in China will be the responsibility of Baiji.
-fold linatumomab is amniocentesic based on its advanced dual-specific T-cell bridging system (BiTE), the first dual-specific antibody product born on amniotic BiTE technology platform, that activates the immune system to identify and kill tumor cells by presenting CD19 proteins on tumor cells to CD3 proteins specifically expressed by T-cells.
has been approved abroad for the treatment of relapsed/resoicable B-cell precursor acute lymphoblastic leukemia (ALL).
sales have risen steadily since 2016, reaching $312 million globally in 2019, according to the company's annual sales figures.
January this year, Baiji Shenzhou and Amjin reached a global cancer strategy, in which Baiji Shenzhou will be responsible for Amjin's three approved or declared oncology drugs in China, Angarve ® (XGEVA® The commercialization and development of plerintomo dual anti-injection drugs in China with suminine anti-injection, KYPROLIS®infusional kafezome and BLINCYTO® injections, and the joint development of 20 anti-tumor pipeline drugs.
Angavi® has been approved in China, in the third quarter of this year in China product revenue of 3.05 million U.S. dollars, which is also the first commercial listing in China by Baiji Shenzhou Anjin products;
the first time, Baiji three-quarter report said that is currently for the upcoming approval of products to prepare for commercial listing work.
has been approved for sale worldwide in two dual-resistance units, Blinatumomab and Roche's Emicizumab.
catumaxomab, the world's first dual-specific antibody previously approved for sale, was de-listed and discontinued in 2017 due to commercial unsuccessfulness.
's Emmys were approved as early as November 30, 2018 for the treatment of the rare disease type A haemophilia, according to the Insight database.
the two dual anti-domestic models sold worldwide have been approved after the import of the Ajin Perintomo double resistance was approved.
。